Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2010 | 12-2009 | 12-2008 | 12-2007 | 12-2006 | |
| Cash Flows From Operating Activities | |||||
| Accounts receivable | 911,000 | -607,000 | 541,000 | -79,167 | -528,785 |
| Other Working Capital | 2,777,000 | -151,000 | 477,000 | -846,636 | -743,157 |
| Other Operating Activity | 3,109,000 | 8,599,000 | 6,187,000 | 7,092,781 | 5,627,781 |
| Operating Cash Flow | $6,797,000 | $7,841,000 | $7,205,000 | $6,166,978 | $4,355,839 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -922,000 | -1,370,000 | -1,417,000 | -2,101,210 | -1,371,472 |
| Net Acquisitions | -354,000 | -2,792,000 | -454,000 | -1,028,166 | -267,965 |
| Purchase Of Investment | -340,000 | -183,000 | -96,000 | N/A | -69,926 |
| Sale Of Investment | 118,000 | 146,000 | 947,000 | 44,878 | 32,156 |
| Purchase Sale Intangibles | -495,000 | -99,000 | -461,000 | N/A | N/A |
| Other Investing Activity | 251,000 | 641,000 | 503,000 | 72,612 | 156,696 |
| Investing Cash Flow | $-1,868,000 | $-4,013,000 | $-1,149,000 | $-3,011,885 | $-1,520,511 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -1,290,000 | -102,000 | -3,059,000 | N/A | N/A |
| Debt Issued | 0 | 1,358,000 | 5,523,000 | N/A | N/A |
| Debt Repayment | -45,000 | -48,000 | -48,000 | N/A | N/A |
| Common Stock Issued | 79,000 | 56,000 | 71,000 | 533,497 | 467,025 |
| Common Stock Repurchased | -16,000 | -57,000 | -3,725,000 | -3,754,646 | -1,347,482 |
| Dividend Paid | -3,205,000 | -3,092,000 | -3,008,000 | -2,795,562 | -2,596,966 |
| Other Financing Activity | -1,094,000 | -889,000 | -662,000 | 4,274,023 | -1,313,285 |
| Financing Cash Flow | $-5,571,000 | $-2,774,000 | $-4,908,000 | $-1,742,688 | $-4,790,708 |
| Exchange Rate Effect | 81,000 | -158,000 | 1,103,000 | 47,904 | -253,674 |
| Beginning Cash Position | 6,368,000 | 5,472,000 | 3,221,000 | 1,763,867 | 3,970,990 |
| End Cash Position | 5,807,000 | 6,368,000 | 5,472,000 | 3,224,175 | 1,761,425 |
| Net Cash Flow | $-642,000 | $1,054,000 | $1,148,000 | $1,412,404 | $-1,955,381 |
| Free Cash Flow | |||||
| Operating Cash Flow | 6,797,000 | 7,841,000 | 7,205,000 | 6,166,978 | 4,355,839 |
| Capital Expenditure | -1,635,000 | -1,873,000 | -2,069,000 | -2,145,080 | -1,589,417 |
| Free Cash Flow | 5,162,000 | 5,968,000 | 5,136,000 | 4,021,898 | 2,766,422 |